Next Article in Journal / Special Issue
Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2
Previous Article in Journal
3,1-Benzothiazines, 1,4-Benzodioxines and 1,4-Benzoxazines as Inhibitors of Matriptase-2: Outcome of a Focused Screening Approach
Open AccessReview

The Role of Immunotherapy in Multiple Myeloma

by Mehmet Kocoglu *,† and Ashraf Badros
Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, MD 21201, USA
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Ashkan Emadi and Dhimant Desai
Pharmaceuticals 2016, 9(1), 3;
Received: 11 November 2015 / Revised: 29 December 2015 / Accepted: 6 January 2016 / Published: 14 January 2016
(This article belongs to the Special Issue Chemotherapeutic Agents)
Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic research efforts towards better understanding of normal and missing immune surveillence in myeloma have led to development of new strategies and therapies that require the engagement of the immune system. Many of these treatments are under clinical development and have already started providing encouraging results. We, for the second time in the last two decades, are about to witness another shift of the paradigm in the management of this ailment. This review will summarize the major approaches in myeloma immunotherapies. View Full-Text
Keywords: myeloma; immunotherapy; vaccines; tumor antigens; antibodies; CAR-T; adoptive cell therapy myeloma; immunotherapy; vaccines; tumor antigens; antibodies; CAR-T; adoptive cell therapy
Show Figures

Figure 1

MDPI and ACS Style

Kocoglu, M.; Badros, A. The Role of Immunotherapy in Multiple Myeloma. Pharmaceuticals 2016, 9, 3.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop